Paratek Pharmaceuticals — Investor Presentation (January 2018)
39 slides from Paratek Pharmaceuticals's investor presentation, Jan 5, 2018
Slide 1: Corporate Presentation January 2018
Corporate Presentation January 2018 Exhibit 99.1
Slide 2: Forward-looking statements disclaimer
Third-party industry and market information included herein has been obtained from sources believed to be reliable, but the accuracy or completeness of such information is not guaranteed by, has not been independently verified by, and should not be construed as a representation by, Paratek. The info
Slide 3: Paratek Investment Highlights
Potential Blockbuster Antibiotic Clear Registration Path: U.S. FDA and EU EMA Modernized Tetracycline: A Promising Antibiotic Profile Positive Ph3 Data in Skin Infections (IV/Oral + Oral only) Positive Ph3 Data in Community Acquired Bacterial Pneumonia (IV/Oral) Established Safety Profile in > 1,900
Slide 4: Experienced Senior Management Team
Experienced Senior Management Team Michael F. Bigham Chairman & CEO Evan Loh, MD President, COO & CMO Led Tygacil Development Doug Pagán Chief Financial Officer Adam Woodrow Chief Commercial Officer Led Tygacil Commercialization William Haskel General Counsel & Corporate Secretary
Slide 5: Omadacycline: A Modernized Tetracycline
Omadacycline: A Modernized Tetracycline First-in-Class Aminomethylcycline: RestoringTetracycline Efficacy by Overcoming Resistance 9-Position Modification: Overcomes Ribosomal Protection 7-Position Modification: Overcomes Efflux Pump No known metabolites No CYP interactions identified No anticipated
Slide 6: Two NDA-Ready Assets
Two NDA-Ready Assets U.S. FDA NDA Approvals Projected in 2018 Research Preclinical Phase 1 Phase 2 Phase 3 Pre-Registration NDA Filing Commercial Rights Omadacycline Sarecycline (U.S.) (ex-U.S.) (Global) UTI (Oral & IV) – QIDP (cUTI / uUTI) ABSSSI (Oral & IV) – QIDP + SPA CABP (Oral & IV) – QIDP + S
Slide 7: Timing of Key Milestones
Timing of Key Milestones U.S. FDA NDA Approvals Projected in 2018 for Both Omadacycline and Sarecycline Omadacycline Events Timing Results ABSSSI Phase 3 data: IV and oral Q2 2016 Positive Phase 3 data UTI Phase 1b data: PK/PD Q4 2016 Proof-of-principle CABP Phase 3 data: IV and oral Q2 2017 Positiv
Slide 8: Omadacycline Commercial Opportunity
Omadacycline Commercial Opportunity Potential Blockbuster Antibiotic in Both Hospital and Community Settings
Slide 9: Omadacycline Possesses a Multitude of Differentiated Attributes
Omadacycline Possesses a Multitude of Differentiated Attributes No Generic Broad Spectrum IV-Oral Hospital Competitors Sources: 1. JMI surveillance 2010, data on file 2. JMI Surveillance 2015, data on file 3. Product Label 4. Anticipated attributes and or activity based on current data 5. In-vitro d
Slide 10: Key Factors Enabling Omadacycline Formulary Endorsement
Key Factors Enabling Omadacycline Formulary Endorsement Multiple Indications with a Bioequivalent(1) IV and Oral Formulation confidential contingency/scenario planning document. for internal discussion purposes only. Omadacycline Ceftaroline Delafloxacin Tedizolid Dalbavancin Oritavancin Multiple Co
Slide 11: Compelling Educational Opportunity Amplifies Unmet Need
Compelling Educational Opportunity Amplifies Unmet Need Awareness at Launch Perception of Resistance to Oral Treatments is Low & Doesn’t Match Reality confidential contingency/scenario planning document. for internal discussion purposes only. Resistance rates for generic oral broad-spectrum antibiot
Slide 12: Hospital Launch: Narrow Spectrum or IV-Only Antibiotic Launches
Hospital Launch: Narrow Spectrum or IV-Only Antibiotic Launches Omadacycline Will Be Competitive with the Best of These Launches Text goes here Launch Dates: Ceftazidime/Avibactam: Apr 2015 Dalbavancin: Jul 2014 Oritavancin: Oct 2014 Ceftolozane/Tazobactam:Dec 2014 Ceftaroline: Jan 2011 Tigecycline:
Slide 13: Hospital Launch: Success Begins with Specialists
Hospital Launch for Omadacycline: Success Begins with Specialists in Years 1-2 Post-Launch IDs Pulmonologists Hospitalists PharmD IDs ER Doctors 1-2 years post launch HOSPITAL Internal Medicine Primary Care Provider NPs, PAs Urgent Care 2+ years post launch COMMUNITY ~6.7M1 ~900k CABP and ABSSSI Pat
Slide 14: Community Promotion 2+ Years Post-Launch Expands The Market
Community Promotion 2+ Years Post-Launch Expands The Market Omadacycline Has the Potential to Realize This Opportunity
Slide 15: Physicians Confirm Unmet Medical Needs
Physicians Confirm Unmet Medical Needs Omadacycline Provides a Valuable Option Source: Paratek sponsored market research Known Safety Profile Established Efficacy in a Monotherapy Equivalent IV & Oral Physicians Recognize the Positive Attributes of Omadacycline Modernized Tetracycline Confidence to
Slide 16: Physician Antibiotic Treatment Decision Priorities
Physician Antibiotic Treatment Decision Priorities Omadacycline Offers Simplified Solutions to a Complicated Treatment Decision Source: Paratek sponsored market research How Confident am I About the Coverage for this Patient? Suspected resistance gram +, gram -, atypical, or anaerobe Potentially pol
Slide 17: Antibiotic Use-Limiting Factors in CABP
Antibiotic Use-Limiting IV-only Formulations & Safety Considerations in CABP Omadacycline: A Convenient Monotherapy Once-Daily Oral-IV Alternative Primary Antibiotic Options in CABP IDSA/ATS Recommends a Targeted Empirical Antimicrobial Therapy(1) Sources: 1. Lionel A. Mandel, Richard Wunderink, Ant
Slide 18: Antibiotic Use-Limiting Factors in ABSSSI
Antibiotic Use-Limiting IV-only Formulations & Safety Considerations in ABSSSI Omadacycline: A Convenient Monotherapy Once-Daily Oral-IV Alternative Primary Antibiotic Options in ABSSSI IDSA Recommends a Targeted MRSA Antimicrobial Therapy1 HOSPITAL confidential contingency/scenario planning documen
Slide 19: Addressable U.S. Hospital Market: ~890K patients
Addressable U.S. Hospital Market: ~890K patients $2.6B Opportunity by 2028 Empiric IV to Oral Monotherapy in Patients Who Fail to Respond or Are Intolerant to Generic Option ABSSSI: Empiric IV to Oral , resistance suspected or intolerant CABP: Empiric IV to Oral , resistance suspected or intolerant
Slide 20: Omadacycline U.S. Timeline to Launch
MSLs Hired Omadacycline U.S. Timeline to Launch (January 2019) MSL Education, Publications, HEOR & Payer Dialogue Complete Submission (NDA Filing) NDA Acceptance Anticipated NDA Action Payer Reimbursement and Trade Discussions Finalize Pricing Scientific Exchange OPDP Review of Marketing Materials A
Slide 21: Focus of Launch Efforts
Focus of Launch Efforts Awareness & Education Leading to Access & Use Advocacy Formulary Access Utilization Scientific Exchange Unbranded Disease State Education Programs Publications HEOR Publications Payer Discussions Guidelines Awareness & Education Access Behavior Change + = Trial Usage Adoption
Slide 22: Pre-Launch and 1st Year Post-Launch Key Deliverables
Pre-Launch and 1st Year Post-Launch Key Deliverables Publications, Payer Reviews, Distributors & Patient Assistance Programs in Place Pre Launch Publications: All phase 3 manuscripts in press OMC CID supplement in press Health value dossier: Budget Impact Model in press Payers: OMC reviewed by major
Slide 23: Omadacycline Efficacy and Safety in ABSSSI and CABP
Omadacycline Efficacy and Safety in ABSSSI and CABP Positive Benefit:Risk Profile Supports Regulatory Path to Approval
Slide 24: Omadacycline OASIS-1 Study Results
Omadacycline OASIS-1 Study Results Achieved Primary Efficacy Endpoints for Both FDA and EMA EMA Co - Primary Endpoints Delta (95% CI) -0.7 (-6.3, 4.9) Delta (95% CI) +2.5 (-3.2, 8.1) Delta (95% CI) +2.8 (-0.9, 7.1) FDA Primary Endpoint Omadacycline Linezolid
Slide 25: Clinical Success at PTE by Baseline Pathogen (OASIS-1)
*S. anginosus group consists of: S. anginosus, S. intermedius, and S. constellatus. MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; VSE, vancomycin-susceptible enterococci. Clinical Success at PTE by Baseline Pathogen (OASIS-1) Highly Effective
Slide 26: Omadacycline OPTIC Study Results
FDA Primary Endpoint 81.1 88.4 92.5 82.7 85.2 90.5 30 20 10 0 40 50 80 70 60 90 100 Early Clinical Response - ITT Omadacycline Moxifloxacin Delta (95% CI) -1.6 (-7.1, 3.8) Clinical Success at PTE - ITT Clinical Success at PTE - CE-PTE Delta (97.5% CI) +3.3 (-2.7, 9.3) Delta (97.5% CI) +2.0 (-3.2, 7.
Slide 27: Clinical Success at PTE by Baseline Pathogen (OPTIC)
Clinical Success at PTE by Baseline Pathogen* (OPTIC) Highly Effective Across Key Gram (+), Gram (–) & Atypical CABP Pathogens Omadacycline (N=204) Moxifloxacin (N=182) Baseline Pathogen N Clinical Success n (%) N Clinical Success n (%) Atypical Pathogens 118 109 ( 92.4) 106 97 ( 91.5) Mycoplasma pn
Slide 28: Omadacycline OASIS-2 Study Results
EMA Co-Primary Endpoints Delta (95% CI) +5.0 (-0.2, 10.3) Delta (95% CI) +3.3 (-2.2, 9.0) Delta (95% CI) +2.3 (-0.5, 5.8) FDA Primary Endpoint Omadacycline OASIS-2 Study Results Achieved Primary Efficacy Endpoints for Both FDA and EMA
Slide 29: Clinical Success at PTE Baseline Pathogen (OASIS-2)
Clinical Success at PTE Baseline Pathogen (OASIS-2) Highly Effective Across Key Gram (+) Skin Pathogens Omadacycline (n=276) Linezolid (n=287) Baseline Pathogen N Clinical Success n (%) N Clinical Success n (%) Staphylococcus aureus 220 182 (82.7) 233 186 (79.8) MRSA 104 89 (85.6) 107 85 (79.4) MSSA
Slide 30: Omadacycline Safety and Tolerability Profile Established
Selected TEAS Occurring in ≥2% of Patients Receiving Omadacycline in the Pooled Phase 3 CABP and ABSSSI Clinical Trials Omadacycline (N = 1073) Linezolid (N = 689) Moxifloxacin (N = 388) Nausea1 14.9 8.7 5.4 Vomiting1 8.3 3.9 1.5 Diarrhea2 2.4 2.9 8.0 Transaminase Elevations Increased 4.3 4.4 5.2 He
Slide 31: Completed Omadacycline Phase 1b UTI Study Design
Completed Omadacycline Phase 1b UTI Study Design Imminent Need to Replace Quinolones in Cystitis Group 1 (n=10) Dose 200 mg IV Day 1 Dose 300 Oral q24h Days 2-5 Screening (≤ 48 hours prior to randomization) End of Treatment (Day 6) Post Treatment Evaluation Follow-Up Group 2 (n=10) Dose 300 mg Oral
Slide 32: Oral Bioavailability Results in High Urine Concentrations
Oral Bioavailability Results in High Omadacycline Concentrations in Urine Supports Development for a UTI Indication Day 5 Day 1
Slide 33: Phase 2 UTI Program Underway
Phase 2 UTI Program Underway Adaptive Dosing Designs Employed in Cystitis and Acute Pyelonephritis Studies ~200 patients oral omadacycline (up to 450mg) 7 days oral nitrofurantoin 7 days Day 14 (+/- 2d) Post-Therapy Evaluation (PTE) Day 1 Day 7 End of Treatment (EOT) Day 30 - 37 Final Follow-up Cyst
Slide 34: Key Financial Information
Key Financial Information Key Metrics 12/31/17 balance Total Cash, Cash Equivalents, and Marketable Securities $152.0 million Gross Long-term Debt Obligation $60.0 million Basic Shares Outstanding 27,941,015 Stock Options, Restricted Stock Units, and Warrants Outstanding 4,897,977 Funding Projected
Slide 35: Equity Research Analyst Coverage
Equity Research Analyst Coverage Paratek Pharmaceuticals, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Paratek Pharmaceuticals, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or pre
Slide 36: Paratek Investment Highlights
Potential Blockbuster Antibiotic Clear Registration Path: U.S. FDA and EU EMA Modernized Tetracycline: A Promising Antibiotic Profile Positive Ph3 Data in Skin Infections (IV/Oral + Oral only) Positive Ph3 Data in Community Acquired Bacterial Pneumonia (IV/Oral) Established Safety Profile in > 1,900
Slide 37: Paratek
& PARATEK
Slide 38: Addressable U.S. Community Market: ~2.1M patients
ABSSSI: Empiric oral treatment, resistance suspected or Intolerant CABP: Empiric oral treatment, resistance suspected or Intolerant UTI: Empiric treatment, ESBL suspected or Intolerant = X = = X = = X = ~5%(2) Need broad sp + MRSA coverage ~6%(3) Need alternative to FQ ~3%(4) Need alternative to FQ
Slide 39: Omadacycline IP Protection and Market Exclusivity
Omadacycline IP Protection and Market Exclusivity GAIN Act Ensures 10 Years of Market Exclusivity Anticipated Patent Term Extension Key Composition of Matter Patent (U.S. 7,553,828) Expires June 2023 Possible 6 month pediatric exclusivity extension 2000 2005 2010 2015 2020 2025 2030 Patent Issued Fi
Paratek Pharmaceuticals — Investor Presentation (January 2018) on 6ix